These findings have served as the basis for an ongoing phase I/II study of GPS in combination with the anti–PD-1 drug pembrolizumab in patients with ovarian cancer and other solid tumors (SLS17-201/MK3475-770; NCT03761914). Here, PDCD1 is linked to ovarian carcinoma.